KMT2A and acute myeloid leukemia: (2023) identified TBL1XR1-RARB and KMT2A-SEPT6 fusions in RARA-negative pediatric AML with APL-like morphology, noting resistance to ATRA/ATO and advocating for RNA-seq to improve diagnostic accuracy (12).